“Despite being in the World Health Organisation’s list of essential medicines, access to good quality asparaginase in India and several other Asian, African and South American countries has been a problem. Approximately 25,000 new cases of acute Lymphocytic Leukemia are diagnosed in India each year,” said Sonawane.
The repeated administration of asparaginase currently in use for treatment of acute Lymphocytic Leukemia patients causes serious side effects such as acute lymphocytic leukemiaergic reactions, neurotoxicity, immunogenicity, hypersensitivity and toxicity to the pancreas, liver and spleen among other organs.
Moreover, due to immunogenic nature of current asparaginase formulations, the treatment of relapse acute Lymphocytic Leukemia is significantly compromised. For these reasons, there is a global search for asparaginase variants with better safety profile.
Similarly, Sengupta got patent for invention on, “Design Space Exploration System and Method thereof using a Bacterial Foraging Optimization Mechanism” that is useful for designing digital chips of camera systems and mobile devices.
The invention is capable to enhance the speed of the chips and reduce power using biological chemotaxis and elimination-dispersal process. The present invention relates to design space exploration (DSE), and more particularly to method and system for design space exploration in high level synthesis using bacterial foraging optimisation mechanism for designing or obtaining an application-specific processor (ASP) or Hardware Accelerator or Intellectual Property Core.
Overall, 75 patents have been filled from the inception of the Institute and total 4 patents have been granted by Indian Patent Office.
Source link
